Abstract
Epidemiological studies have linked platelet hyperactivity with an increased risk of vascular events. Even more convincing is the evidence from appropriately designed clinical trials showing that antiplatelet agents decrease the risk of vascular events (e.g. myocardial infarction, MI and stroke). These findings are compatible with the known thrombotic action of platelets. A considerable limitation in platelet research is the absence of a reliable, universally accepted marker of platelet activity. Therefore, it is difficult to reliably identify the ‘high risk patient’ and/or evaluate the efficacy of any administered treatment other than by calculating event rates over a period of time. This review will focus on the preventive aspects of antiplatelet intervention while also briefly considering the assessment of platelet hyperactivity and the mechanisms involved in platelet-induced thrombosis.
Keywords: Platelet, aggregation, thrombosis, aspirin, clopidogrel, myocardial infarction, stroke
Current Pharmaceutical Design
Title: Platelets and Vascular Risk: An Option for Treatment
Volume: 13 Issue: 16
Author(s): I. A. Jagroop, A. I. Kakafika and D. P. Mikhailidis
Affiliation:
Keywords: Platelet, aggregation, thrombosis, aspirin, clopidogrel, myocardial infarction, stroke
Abstract: Epidemiological studies have linked platelet hyperactivity with an increased risk of vascular events. Even more convincing is the evidence from appropriately designed clinical trials showing that antiplatelet agents decrease the risk of vascular events (e.g. myocardial infarction, MI and stroke). These findings are compatible with the known thrombotic action of platelets. A considerable limitation in platelet research is the absence of a reliable, universally accepted marker of platelet activity. Therefore, it is difficult to reliably identify the ‘high risk patient’ and/or evaluate the efficacy of any administered treatment other than by calculating event rates over a period of time. This review will focus on the preventive aspects of antiplatelet intervention while also briefly considering the assessment of platelet hyperactivity and the mechanisms involved in platelet-induced thrombosis.
Export Options
About this article
Cite this article as:
Jagroop A. I., Kakafika I. A. and Mikhailidis P. D., Platelets and Vascular Risk: An Option for Treatment, Current Pharmaceutical Design 2007; 13 (16) . https://dx.doi.org/10.2174/138161207780831383
DOI https://dx.doi.org/10.2174/138161207780831383 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Combinations of Renin-Angiotensin-Aldosterone System Antagonists:True Advantages?
Current Pharmaceutical Design Dietary Fish Oil Reduces Colon Cancer Risk
Current Organic Chemistry Antithrombotic Treatment in the Prevention of Ischemic Stroke
Current Drug Targets Lithium and its Neuroprotective and Neurotrophic Effects: Potential Treatment for Post-Ischemic Stroke Sequelae
Current Drug Targets Genes Involved in Hereditary Hearing Impairment
Current Genomics Caregiver Burden in Fragile X Families
Current Psychiatry Reviews Opioid-induced Cardioprotection
Current Pharmaceutical Design Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy
Current Drug Targets Potential of Flavonoids as Anti-inflammatory Agents: Modulation of Pro- Inflammatory Gene Expression and Signal Transduction Pathways
Current Drug Metabolism Clinical Profile of Relaxin, a Possible New Drug for Human Use
Current Drug Safety Progress in the Development of Aminopeptidase N (APN/CD13) Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Depression in Coronary Heart Disease Patients: Etiological and Screening Issues
Current Psychiatry Reviews The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Combination of Statin Plus Renin Angiotensin System Inhibition for the Prevention or the Treatment of Atherosclerotic Cardiovascular Disease
Current Pharmaceutical Design Mass Spectrometric Analysis of F2-Isoprostanes: Markers and Mediators in Human Disease
Current Pharmaceutical Analysis Serum Interleukin-33 is a Predictor of Depression in Patients with Acute Ischemic Stroke
Current Neurovascular Research Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications
Current Medicinal Chemistry Endothelial Dysfunction and Inflammation in Ischemic Stroke Pathogenesis
Current Pharmaceutical Design Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design